Clinical Trials Directory

Trials / Completed

CompletedNCT00738855

Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO)

Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO).

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Mansoura University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Mini abstract : Altogether 100 patients with 117 episodes of ASBO were randomized into control and gastrografin groups. Eight episodes in eight patients were excluded. Gastrografin group showed a significant decrease of both the time between admission and operation and that of hospital stay .The need for surgery was reduced but statistically insignificant.

Detailed description

Abstract Background: Many published studies have shown that Gastrografin can be used for diagnosis post operative acute small bowel obstruction (ASBO) and assessing the need for surgical intervention .However,the studies have reported conflicting results hence the aim of our study to test this hypothesis. Patients and methods : Altogether 100 patients with 117 episodes of ASBO were randomized into control and gastrografin groups in a double blinded fashion. Eight episodes in eight patients were excluded due to protocol violation. In Gastrografin group,100 ml of the dye administered through a nasogastric tube and complete obstruction has been considered if the contrast failed to reach the colon on the 24-hour film. Patients were operated on only if they developed signs of strangulation or failed to improve within 48 hours.

Conditions

Interventions

TypeNameDescription
OTHEROral Gastrografin100 ml of the dye administered through a nasogastric tube
OTHERNothing per osA nasogastric tube

Timeline

Start date
2006-02-01
Primary completion
2008-01-01
Completion
2008-01-01
First posted
2008-08-21
Last updated
2008-11-26

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT00738855. Inclusion in this directory is not an endorsement.